
Today on Drug Discovery & Development
8 considerations to boost clinical trial productivity with AI while dodging hallucination hurdles
The development of new drugs is undeniably a data-intensive endeavor. Despite impressive advances in AI over the past years, researchers often continue to grapple with crushing data volumes. This hurdle is particularly apparent in clinical trials, where crucial data is often stored in machine-unfriendly formats such as PDFs, PowerPoint or HTML or other formats. This article explores…A timeline of Merck’s legal battle over Medicare negotiation
Marking the first legal challenge of its kind, pharma giant Merck & Co. took to the courts on Tuesday, directly contesting the U.S. government over the Medicare drug price negotiation program. The Big Pharma company’s lawsuit, filed in the U.S. District Court for the District of Columbia, contends the program’s basis — the Inflation Reduction…Drug Discovery and Development See More >

Expanding genomic analysis: Inside NVIDIA Parabricks integration with Amazon Omics
Following the recent expansion of Amazon Omics, as covered in our previous article “Ready, set, analyze: Amazon Omics unveils new Ready2Run workflows”, we wanted to explore the role of third-party providers in shaping the landscape of genomic analysis and bioinformatics. NVIDIA is one of these providers. The GPU company has worked to integrate their Parabricks…

A timeline of Merck’s legal battle over Medicare negotiation

Beyond the trip with non-hallucinogenic psychoplastogens in neuropsychiatry

2023 investment outlook reveals resilient life sciences sector despite funding fluctuations

Decoding Bayer’s digital health leap and its implications on drug discovery and personalized medicine
Sponsored Content See More >
Genomics/Proteomics See More >

Decoding the enigma of the commander complex: Employing AlphaFold2 to illuminate biological structures
Machine learning algorithms, such as Alphabet’s neural network-based model AlphaFold2, are steadily transforming medical research, shedding light on complex biological structures. A recent case in point involves research using the technology to explore the Commander complex, a 16-protein complex crucial for cellular protein transport processes. This complex is not only vital for normal cellular function,…
Infectious Disease See More >

Codagenix taps synthetic biology and machine learning in vaccine development
In the quest to outsmart viral foes such as SARS-CoV-2, RSV and influenza, Codagenix, a clinical-stage biotech firm based in Farmingdale, New York, has engaged a unique arsenal: the intersection of synthetic biology and machine learning. Their weapon of choice is a blend of live-attenuated virus design and codon deoptimization technology. Their process involves introducing…

An overview of the RSV vaccine landscape: What comes after GSK’s approval of Arexvy?

Unraveling the impact of FDORA and PREVENT Pandemics Acts on the life sciences

The 50 best-selling pharmaceuticals of 2022: COVID-19 vaccines poised to take a step back

FDA authorization of vilobelimab signals new opportunities for drug developers in inflammatory diseases
Oncology See More >

CLN-619 antibody therapy offers a new hope for patients with advanced solid tumors
Boston-based Cullinan Oncology has unveiled data for its new monoclonal antibody therapy, CLN-619, ahead of the American Society of Clinical Oncology (ASCO) 2023 meeting scheduled for June 2–6 in Chicago. The drug could potentially offer a new treatment option for patients with advanced solid tumors. Dr. Judy Wang, Associate Director of Drug Development at the…

Insilico Medicine wins IND approval for AI-designed USP1 inhibitor for cancer trials in U.S. and China

Pharma M&A resurgence: An overview of recent deal-making trends

The 50 best-selling pharmaceuticals of 2022: COVID-19 vaccines poised to take a step back
